Ocuphire Pharma Investor Day Presentation Deck
RM
50
MIRA-2: Participant Characteristics
MIRA-2 Study was Balanced Across Both Nyxol and Placebo Groups
Age (years): Median (Range)
Sex: Male n (%)
Female n (%)
Race: White n (%)
African American n (%)
Asian n (%)
Other^ n (%)
^includes American Indian or Alaska Native; Native
Hawaiian or Other Pacific Islander
Dark Iris Color: n (%)
Light Iris Color: n (%)
Baseline Pupil Diameter Mean (mm)
Max Dilated Pupil Diameter Mean (mm)
Nyxol
n=94
31 (12-70)
Source: MIRA-2 TLR table # 14.1.2.3 (mITT)
36 (38%)
58 (62%)
70 (75%)
17 (18%)
6 (6%)
2 (2%)
49 (52%)
45 (48%)
5.09
7.21
MIRA-2 Phase 3 Trial
Placebo
n=91
30 (13-73)
36 (40%)
55 (60%)
7.28
74 (81%)
16 (18%)
3 (3%)
1 (1%)
46 (51%)
45 (50%)
5.18
Accommodation Median (diopters)
Note: 14 pediatric subjects 12-17 years old were enrolled in the trial; Race is more than 100% given subjects could check more than one category.
7.20
7.41
Total
n=185
31 (12-73)
72 (39%)
113 (61%)
144 (78%)
33 (18%)
9 (5%)
3 (2%)
95 (51%)
90 (49%)
5.13
7.20
7.41
Ocuphire
PHARMAView entire presentation